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A B S T R A C T
Cryptococcus neoformans is a leading cause of invasive cryptoccocal infections which include meningitis/meningo-
encephalitis, cerebral cryptococcoma, invasive pulmonary and mediastinal infection. Invasive infection is mainly diag-
nosed in immunocompromised patients, especially in HIV-infected individuals. There is a rising number of patients with
invasive cryptococcal infections in immunocompromised patients who are HIV-negative. Among several primary immu-
nodeficiency syndromes, considered as possible reasons for these invasive infections, idiopathic CD4+ T lymphocyto-
penia (ICL) is most frequently diagnosed. The pathogenesis of this rare syndrome is still unknown, while its clinical
spectrum ranges from an asymptomatic laboratory abnormality to life-threatening opportunistic infections. Here we pre-
sent an HIV-negative young man suffering from cryptococcal meningoencephalitis in whom ICL was diagnosed.
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Introduction
Cryptococcus is a worldvide-spread encapsulated yeast
(Basidiomycetes) which can be isolated from animals and
animal-based food, pigeon droppings and fruit1–3. Crypto-
cocci are normal human colonizators, while infection
with this yeast is usually seen in immunocompromised
individuals4. Cryptococcus neoformans is the leading cau-
se of invasive cryptococcal infection worldvide. This fun-
gus, as mentioned before, usually causes infections in
immunocompromised patients, especially in HIV-infec-
ted individuals5. Following the emergence of the HIV-re-
lated immunodeficiency syndrome, Cryptococcus neofor-
mans meningitis was rapidly recognized among the most
frequent opportunistic infections in both the United Sta-
tes and rest of the world5–7. Invasive cryptococcal infections
besides meningitis or meningoencephalitis, otherwise in-
clude cerebral cryptococcoma, invasive pulmonary and
mediastinal infection and prostate infection in males. Al-
though the literature in general refers to the meningeal
syndrome as cryptococcal meningitis, the correct histo-
pathologic term for this condition would be meningo-
encephalitis, because in most autopsied cases there is a
clear evidence of both involvement of the meninges and
the underlying brain parenchyma8. Invasive neural in-
fection is usually caused by species complex C. neofor-
mans var grubii (serotype A), or C. neoformans var
neoformans (serotype D). Cryptococcus gatii (serotypes B
and C) is recognized as a species distinct from C. neo-
formans and almost always affects individuals with no
identifiable immune impairment in whom pulmonary
and brain mass lesions are common9. Predomination of
different serotypes may depend on the presence or ab-
sence of an underlying condition (imunocompetent versus
immunocompetent hosts) and geographic distribution10.
Other non-neoformans cryptococcal species responsible
for invasive fungal disease include Cryptococcus laurentii
(recently reclassified as Cryptococcus flavescens) and
Cryptococcus albidus, but these fungi are infrequently
found in humans and do not have a selective tropism for
the central nervous system (CNS) as C. neoformans11.
Moreover, infection with these cryptococcal species is
usually seen in patients following antifungal treatment12.
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Following inhalation, cryptococcal spores are depos-
ited into the pulmonary alveoli and meningitis occurs
from hematogenous dissemination of the fungus from
the lungs. The disease is often difficult to diagnose.
Headache and fever are prominent symptoms at the on-
set of CNS involvement, other symptoms of meningitis
may arise subsequently (vomiting, photophobia, menin-
gismus). The headache, intermittent at the onset, is
mostly localized in the frontal and temporal regions, but
with disease progression it becomes continuous and pro-
gressively severe. Visual disturbances such as diplopia
and photophobia are also early symptoms of the disease.
Other ocular disorders include strabismus, nystagmus,
anisocoria, ptosis, neuroretinitis, retinal hemorrhages,
optic nerve atrophy and ophthalmoplegia. Papilledema is
present in half of active cases, due to increased spinal
fluid pressure13.
The CD4+ T lymphocyte count in HIV-infected pa-
tients determines the rate of immunological function of
patients and the susceptibility to opportunistic infec-
tions. Although not generally accepted, some physicians
still use the number of CD4+ T cells as a surrogate
marker for HIV infection, mostly in patients who present
with unusual infections14. Invasive cryptococcal infec-
tions occur in HIV-infected individuals especially when
the HIV-associated immunodeficiency is severe, as ex-
pressed by a CD4+ T lymphocyte count below 50–100
cells/mL5,15,16.
In recent years there is a rising number of reports of
opportunistic infections, including cryptococcal infections
in immunocompromised individuals who are HIV-unin-
fected. Several primary immunodeficiency syndromes
are also considered as a possible underling condition for
cryptococcal infections, among which idiopathic CD4+ T
lymphocytopenia (ICL) is most frequently diagnosed. Pa-
tients suffering from ICL have low numbers of CD4+ T
cells, without serologic confirmation of HIV infection
and no history of previous immunodeficiency or therapy
associated with depletion of T cells17,18. ICL is a rare dis-
ease and still described as an occasional result in analyz-
ing the pathogenesis of immunodeficiency in HIV-nega-
tive patients19. Pathogenesis of this immunodeficiency is
still not elucidated and several mechanisms of the dis-
ease are proposed: defective generation of CD4+ T cell
precursors in patients presented with low levels of
CD34+CD38–DR+ hematopoetic stem cells20, insufficient
production of IL-2 and TNF-a necessary for T cell pro-
liferation21, increased apoptosis of CD4+ T cells21, and
most recent, impaired expression of CXCR4 receptor on
the surface of CD4+ T cells, necessary for IL-2 mediated
induction of CD4+ T cell proliferation22.
Case Report
A previously healthy 28 year old man was addmited to
the Clinic of Infectious Diseases at the Clinical Hospital
Center Rijeka in December 2005 with a 3-day history of
mild fever (up to 38 °C) and intermittent headache. Sev-
eral hours before admission the patient vomited, noticed
tremor and experienced speach difficulties (slurred speech
followed by complete aphonia). The patient was in a
steady monogamous heterosexual relationship. There was
no history of blood transfusion, injection drug use or re-
cent travel. He owned a pet dog and has been occasionally
visiting a countryside farmstead where his relatives kept
poultry. The patient did not have a history of frequent in-
fections, thrush, fever or weight loss. There was no short-
ness of breath, cough or hemoptysis before admission.
Physical examination on addmision revealed that the
patient was mildly dehydrated, psychically disorientated
and restless. He had normal cardiovascular and respira-
tory function, reactive mydriasis, negative signs of men-
ingeal invlovment and no evident focal neurological defi-
cit. There were no skin lesions, and lymphadenopathy or
splenomegaly were also not present.
Laboratory tests revealed a leukocyte count of 8.9´
109/L (granulocytes 7.1´109/L, lymphocytes 1.6´109/L),
and a normal red blood cell and thrombocyte count. The
serum C-reactive protein was 11 mg/L, the plasma so-
dium and potassium levels were 131 mmol/L and 3.0
mmol/L respectively. A chest radiograph revealed scar
tissue in the upper left pulmonary lobe. Brain computer
tomography (CT) was normal. A lumbar puncture re-
vealed pleocytosis in the cerebrospinal fluid (CSF) with a
leukocyte count of 478´106/L (88% of neutrophils, 9% of
lymphocytes and 3% of monocytes), proteinorachia of
1.38 g/L, mildly increased lactate levels of 2.23 mmol/L,
decreased chloride levels of 113 mmol/L and a normal se-
rum/CSF glucose ratio (6.4/3.7 mmol/L). The patient was
initially treated with acyclovir (3´10 mg/kg i.v.). Adi-
tional lumbar punctures were performed with similar
CSF cell counts; the leukocyte count range was from 177
to 320´106/L cells (mononuclear cells: 51–60%). The CSF
glucose level was low (down to 0.8 mmol/L) and the pro-
tein levels were somewhat more increased as compared
to the initial CSF analysis (1.86 g/L). Antituberculosis
drugs were given in view of these CSF findings. The pa-
tient occasionally complained of vertigo, blurred vision
and diplopia. CSF cultures revealed no bacteria, includ-
ing Mycobacterium tuberculosis (TB) in any of the sam-
ples tested. However, India ink staining of the last two
CSF samples (of five) revealed encapsulated budding
yeast cells consistent with Cryptococcus neoformans.
This result was confirmed with CSF fungal culture. C.
neoformanswas sensitive to amphotericin B, fluconazole,
itraconazole and 5-fluorocytosine. Antituberculotics we-
re discontinuated and the patient initially received treat-
ment with amphotericin B (0.35 mg/kg daily for two
days, followed with 0.7 mg/kg daily) for four weeks. Eight
days after antifungal treatment was initiated, the pa-
tient was transferred to University Hospital of Infectious
Diseases »Dr. Fran Mihaljevi}« in Zagreb, Croatia for ad-
ditional diagnostic procedures, further treatment and
follow up. During the course of treatment papilledema
was also observed; it lasted for one month. He was dis-
charged from the hospital in a good general condition
and further treatment with oral fluconazole (400 mg/
day) was recommended for additional eight weeks.
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Immunocytological analysis of the patient blood sam-
ples revealed significantly decreased CD4+ T lymphocyte
count (236´106/L) which indicated the possibility of un-
derlying HIV infection. However, HIV 1 and HIV 2 anti-
bodies were negative as determined by both enzyme
linked immunosorbent assay (ELISA) and Western blot.
Furthermore, we performed polymerase chain reaction
(PCR) analysis for HIV RNA, which was also negative.
The patient’s CD8+ T cell, B cell, NK cell count and im-
munoglobulin profile were within the normal range. Pa-
tient was HBsAg, anti-HCV, tuberculin test, TPHA and
VDRL negative.
During 34 months of follow-up we observed no disease
relapse. The patient continued to have a depleted CD4+
T cell count (139–193´106/L) and increased levels of
CD3–CD56+ cells (35–54%; normal to 15%) but with no
signs of myeloproliferation or isolated NK-cell prolifera-
tion, and normal phagocyte function of both monocytes
and granulocytes. Immunological tests were all negative
showing existence of no autoantibodies or any collagen
disease. The results of a repeat HIV testing were nega-
tive. ELISA analysis showed the patient to be IgM anti-
-CMV and anti-EBV negative, IgG anti-CMV and anti-
-EBV positive. PCR analysis detected EBV DNA but not
CMV DNA in the serum. Repeated ELISA testing show-
ed persistence of IgG EBV VCA antibodies, IgG EBNA
antibodies and IgG EBV EA antibodies. IgM EBV VCA
antibodies were not detected, however, EBV viremia per-
sisted suggesting chronic EBV infection.
Fungal cultures of repeated CSF samples were nega-
tive from 2 weeks after the initiation of treatment with
amphotericin B. However, in CSF, serum and urine sam-
ples cryptococcal antigen was positive by latex agglutina-
tion in the next 6 months. Fluconazole treatment (400
mg daily) was given for a total of 9 months. At the end of
treatment the patient´s CSF findings were normal, fun-
gal cultures were negative and no cryptococcal antigen
was detected. Antifungal prophylaxis with 100 mg of oral
fluconazole daily and Pneumocystis carinii prophylaxis
(PCP) with oral trimethoprim-sulfamethoxazole 960 mg
every second day was given. A follow-up brain CT scan
was also normal. The patient decided to stop PCP and
antifungal prophylaxis treatment after 24 months.
Discussion and Conclusion
We report a patient with meningoencephalitis caused
by Cryptococcus neoformans. The patient was not HIV
infected and had no apparent underlying immunodefi-
ciency at presentation. During his follow-up it became
clear that he had persistently depressed CD4+ T cell
counts in the absence of other underlying condition;
therefore the observed immunodeficiency in this case is
most probably explained by the idiopathic CD4+ T lym-
phocytopenia (ICL) syndrome.
Confirmed chronic EBV infection in our patient re-
quired further follow-up since ICL can precede, and may
indicate the presence of several malignant diseases, among
which Burkitt’s lymphoma is associated with EBV in-
fection23. However, persistent EBV viremia can not ex-
plain CD4+ T cell immunodeficiency since CD4+ T cells
are normally preserved and completely functional in la-
tent EBV infection and EBV-infected healthy donors24.
Increasing number of cases with decreased or severely
low CD4+ T lymphocyte counts in the absence of HIV in-
fection, or other apparent underlying immunodeficiency
have been recently reported. The US Centers for Disease
Control and Prevention designated this new syndrome as
idiopathic CD4+ T lymphocytopenia18. Other immunode-
ficiency syndromes can also present with low CD4+ T cell
count. Among primary immunodeficiency syndromes pa-
tients with common variable immunodeficiency have low
CD4+ T cell counts but these patients have generally low
levels of immunoglobulins which differences them from
ICL where immunoglobulin levels are usually in the nor-
mal range25. Circadian rhythm, corticosteroid adminis-
tration, severe physical and psychological stress and ad-
vanced age are also been considered to influence the
CD4+ T cell count26,27. Interestingly, cryptococcal infec-
tion by itself may induce CD4+ T cell deficiency through
blocking the cell-mediated immunity through suppressor
T cell functions28. Although not completely elucidated,
ICL is considered to have a good long-term prognosis, the
patients are usually clinically stable, without ongoing
immunological deterioration19. A variety of opportunistic
infections is described in patients suffering from ICL
among which cryptococcal infection presents with men-
ingitis, pulmonary involvement and invasive or dissemi-
nated infections29–31.
Cryptococcus neoformans infection is common in im-
munocompromised patients, especially in patients with
acquired immunodeficiency syndrome (AIDS)5. The dis-
ease is sometimes difficult to diagnose and can be mis-
diagnosed with other infectious causes of meningitis
(fungal, mycobacterial, bacterial, viral), syphilis, lym-
phoma, mass lesions, intoxication, HIV encephalopathy,
trauma, epilepsy, schizophrenia or even bipolar disor-
der32. Serum cryptococcal capsular antigen is a sensitive
and specific serological test for acute cryptococcal menin-
gitis. However, in HIV-positive patients ongoing monitor-
ing of antigen presence during suppressive therapy is not
predictive of disease relapse. This phenomenon may not
be attributable to patients with ICL since several cases of
cryptococcal meningitis in patients with this syndrome
show persistent cryptococcal antigenemia without signs
of meningitis28. It is worth mentioning that in our case
serum cryptococcal antigenemia was low from the onset
of the disease although there was a clear evidence of
meningitis.
Prolonged secondary prophylaxis of cryptococcal in-
fection in HIV-infected patients today is overcame by
successful highly active antiretroviral therapy (HAART)
induced immune reconstitution, and presently is consid-
ered unnecessary in patients with CD4+ T cell count over
200/mL9,33,34. Immune reconstitution inflammatory syn-
drome is also described in patients showing improve-
ment in CD4+ T cell counts following HAART and is
characterized by atypical manifestation of opportunistic
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infections, including cryptococcal pulmonary disease,
meningitis or lymphadenitis35. In ICL patients, until re-
cently, there were no formal recommendation on second-
ary prohylaxis and, as in our case, patients mainly recei-
ved antifungal prophylaxis for a prolonged time period. It
is worth to point out that in the current Infectious Dis-
eases Society of America issued Clinical practice guide-
lines for the management of cryptococcal disease ICL is
not specificaly addressed, however, in non-HIV-infected
and non-transplant hosts maintenance therapy with flu-
conazole for 6 to 12 months is recommended36.
In conclusion, we described a patient with the idio-
pathic CD4+ T cell immunodeficiency syndrome and
cryptococcal meningitis. This case highlights the fact
that CD4+ T cell immunodeficiency can exist in the ab-
sence of laboratory evidence of HIV infection. Finally,
HIV negative patients who present with CNS crypto-
coccosis without an apparent immunodeficiency should
be evaluated for the presence of CD4+ T cell immunodefi-
ciency.
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MENINGOENCEFALITIS UZROKOVAN CRYPTOCOCCUS NEOFORMANS-OM U BOLESNIKA
S IDIOPATSKOM CD4+ T LIMFOCITOPENIJOM
S A @ E T A K
Cryptococcus neoformans naju~estaliji je uzro~nik invazivnih kriptokokoza koje uklju~uju kriptokokni meningo-
encefalitis, mo`dane apscese (tzv. mo`dane kriptokokome), kriptokokozu plu}a i infekciju medijastinuma. Invazivne
kriptokokne infekcije uglavnom poga|aju bolesnike s o{te}enom imunosti, posebice osobe inficirane HIV-om. Ipak,
opisani su brojni slu~ajevi invazivnih kriptokoknih infekcija u osoba s nedostatnom imuno{}u koji nemaju dokazanu
HIV infekciju. Me|u nekoliko primarnih sindroma imunodeficijencije koji bi mogli biti razlogom invazivne kriptokokne
infekcije, sve u~estalije se opisuje idiopatska CD4+ T limfocitna imunodeficijencija. Patogeneza ove bolesti nije do kraja
razja{njena, a klini~ka slika u oboljelih varira od asimptomatske, laboratorijski potvr|ene bolesti do te{kih oportu-
nisti~kih infekcija. U ovom radu smo prikazali slu~aj imunodeficijentne HIV-negativne osobe oboljele od kriptokoknog
meningoencefalitisa uzrokovanog gljivom Cryptococcus neoformans. Kod bolesnika je dokazana idiopatska CD4+ T lim-
focitna imunodeficijencija.
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